SAP's End-2-End Digital Validation Platform Initiative
SAP provides a modern toolchain for the implementation and operation of its software solutions, including Signavio, SAP Cloud ALM and test automation tools. For pharmaceutical and medical technology companies, SAP integrates computer system validation via an End-2-End Digital Validation Platform (E2E DVP) initiative into this toolchain.
This initiative enables the complete digitalization of validation processes within the SAP system landscape – seamlessly and fully integrated into SAP’s own IT processes managed via SAP Cloud ALM.
A central element of this digital validation solution is the DHC Smart Validation Accelerator (SVA). In this webinar, we present the architecture and functionality of the E2E Digital Validation Platform (DVP) and the Smart Validation Accelerator (SVA) – practically and complemented by a system demo.
Webinar Content
- SAP strategy and challenges in validation
- Presentation of SAP’s “End-to-End Digital Validation Platform” initiative
- Overview of the DHC Smart Validation Accelerator for digitalizing SAP validation documentation
- System demo
Dates
Wednesday, May 20, 2026, 10:00 – 10:45 AM
Can’t make these dates? Register anyway to secure access to the free podcast! You will receive the access details automatically shortly after the web session.
Target Audience
This webinar is aimed at specialists and executives in pharma and medical technology involved in the implementation and validation of SAP.
Your Benefits
- Knowledge of the SAP toolchain for life sciences
- Better understanding of SAP’s End-2-End Digital Validation Platform initiative
- Overview of the DHC Smart Validation Accelerator functionalities for digitalizing SAP validation
- Decision basis for using the SAP toolchain in regulated companies
- Strategy for replacing the SAP Solution Manager in the regulated environment with SAP Cloud ALM
Participation and Registration
Our web sessions are a free service for customers and prospects of DHC.
IT service providers and consultants are excluded from participation.
The number of participants is limited.